Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07842770
Recruiting Not applicable

TMS for Sympathetic Hyperactivity and Inflammation in Acute Myocardial Infarction

NCT07842770 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Hospital
Phase
Not applicable
Started
2026-05-17
Last updated
2026-09-25

Condition(s) studied

Acute Myocardial Infarction (AMI)

Investigational drug(s) / intervention(s)

1-Hz repetitive transcranial magnetic stimulation (rTMS)Sham repetitive transcranial magnetic stimulation (sham rTMS)

1-Hz repetitive transcranial magnetic stimulation (rTMS): 1 Hz low-frequency repetitive transcranial magnetic stimulation targeting the right dorsolateral prefrontal cortex, delivered once daily for 7 consecutive days. The stimulation is given on top of standard medication for acute myocardial infarction.

Sham repetitive transcranial magnetic stimulation (sham rTMS): Sham repetitive transcranial magnetic stimulation with identical coil placement, operation noise and treatment schedule, without real magnetic field output. The intervention is delivered once daily for 7 consecutive days, combined with standard medical therapy for acute myocardial infarction.

Study summary

The goal of this clinical trial is to learn whether repetitive transcranial magnetic stimulation (rTMS) can improve sympathetic hyperactivity and inflammatory responses in patients with acute myocardial infarction (AMI), as well as evaluate its safety and tolerability. The main questions it aims to answer are:

Can 1-Hz low-frequency rTMS targeting the right dorsolateral prefrontal cortex improve heart rate variability (SDNN) among patients with acute myocardial infarction? Is rTMS safe and well-tolerated for patients with acute myocardial infarction?

Researchers will compare real rTMS versus sham rTMS to see if real rTMS can reduce sympathetic over-activation and inflammation in AMI patients.

Participants will:

* Receive either real repetitive transcranial magnetic stimulation or sham stimulation for 7 consecutive days on top of standard-of-care medication for AMI
* Complete clinical assessments including electrocardiogram, Holter monitoring, echocardiography, blood laboratory tests for inflammatory markers at baseline, day 7, day 30, and 3-month follow-up
* Undergo resting-state functional magnetic resonance imaging (rs-fMRI) scans at baseline and day 7
* Fill out psychological and quality-of-life questionnaires (PHQ-9, SF-36) at scheduled study visits
* Attend follow-up clinic visits to record adverse events and major adverse cardiovascular events

Eligibility

Sex
ALL
Min age
30 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Aged 30 to 75 years (inclusive), no restriction on sex; 2. Diagnosed with acute myocardial infarction (AMI) in accordance with the Fourth Universal Definition of Myocardial Infarction (2018 ESC/ACC/AHA/WHF), with typical clinical manifestations, electrocardiographic changes and dynamic elevation of cardiac biomarkers; 3. Received standardized reperfusion therapy (thrombolysis or percutaneous coronary intervention, PCI) with hemodynamic stability; 4. Killip class I-II; 5. Evidence of sympathetic activation: resting heart rate ≥90 beats per minute (after excluding confounders such as fever, thyroid dysfunction and severe anemia); reduced heart rate variability (e.g., SDNN \<100 ms) or frequency-domain indices indicating sympathetic predominance (e.g., elevated LF/HF ratio). Exclusion Criteria: 1. Severe cardiac dysfunction: Killip class ≥ III, or left ventricular ejection fraction (LVEF) \<30%; 2. Contraindications to TMS: history of seizure, intracranial surgery or cranial trauma, intracranial/intra-cranial metallic implants, implanted pacemaker or implantable cardioverter-defibrillator; 3. Active severe infection, ongoing anti-tumor treatment, or severe hepatic/renal insufficiency (judged comprehensively by clinical and laboratory findings); 4. Pregnant or breastfeeding women, or those with definite pregnancy plan during the study period; 5. Alcohol or substance dependence, psychiatric or cognitive disorders resulting in poor adherence; 6. Participation in another interventional clinical trial within the past 3 months that may interfere with interpretation of study results; 7. Prior TMS treatment for other diseases; 8. Other conditions judged by investigators to make the participant unsuitable for enrollment (e.g., uncontrolled persistent myocardial ischemia, refractory arrhythmia, need for urgent cardiac surgery).

Primary outcome measure(s)

  • Change in heart rate variability (SDNN) from baseline to day 7 — Baseline and Day 7 (end of treatment)

Trial sites (1)

FacilityCityRegionStatus
Beijing Hospital, National Center of Gerontology Beijing Beijing Municipality Recruiting

More Beijing Hospital trials in China

Identification for High Risk of Coronary Heart Disease Based on Quantitative Analysis of Fundus Vessels and Metabolic Molecules Recruiting
ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC Recruiting
Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients Recruiting
Electroacupuncture Treatment for Discogenic Low Back Pain Recruiting
Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia Recruiting

Other trials for the same condition

Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV) Recruiting
Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction Starting soon
Myocardial Infarction and Periodontitis: Periodontal Health Intervention. Recruiting
Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction Starting soon
POCT Detection for Blood Concentration of Tirofiban in Acute Myocardial Infarction Based on Azo-POP Probe. Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07842770 on ClinicalTrials.gov ↗ ← All trials in China